Mirum Pharmaceuticals Inc (NASDAQ:MIRM) — Market Cap & Net Worth
Market Cap & Net Worth: Mirum Pharmaceuticals Inc (MIRM)
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) has a market capitalization of $5.82 Billion ($5.82 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3250 globally and #1103 in its home market, demonstrating a 4.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mirum Pharmaceuticals Inc's stock price $96.53 by its total outstanding shares 60341617 (60.34 Million). Analyse Mirum Pharmaceuticals Inc cash conversion from operations to see how efficiently the company converts income to cash.
Mirum Pharmaceuticals Inc Market Cap History: 2019 to 2026
Mirum Pharmaceuticals Inc's market capitalization history from 2019 to 2026. Data shows growth from $1.48 Billion to $5.82 Billion (34.02% CAGR).
Index Memberships
Mirum Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.24% | #69 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.02% | #351 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.35% | #46 of 263 |
Weight: Mirum Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mirum Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mirum Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.14x
Mirum Pharmaceuticals Inc's market cap is 9.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.05 Billion | $11.00 Million | -$103.27 Million | 95.78x | N/A |
| 2021 | $962.45 Million | $19.14 Million | -$83.99 Million | 50.29x | N/A |
| 2022 | $1.18 Billion | $77.06 Million | -$135.66 Million | 15.27x | N/A |
| 2023 | $1.78 Billion | $186.37 Million | -$163.41 Million | 9.56x | N/A |
| 2024 | $2.50 Billion | $336.89 Million | -$87.94 Million | 7.41x | N/A |
| 2025 | $4.77 Billion | $521.31 Million | -$23.36 Million | 9.14x | N/A |
Competitor Companies of MIRM by Market Capitalization
Companies near Mirum Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Mirum Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Mirum Pharmaceuticals Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Mirum Pharmaceuticals Inc's market cap moved from $1.48 Billion to $ 5.82 Billion, with a yearly change of 34.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.82 Billion | +22.21% |
| 2025 | $4.77 Billion | +91.03% |
| 2024 | $2.50 Billion | +40.07% |
| 2023 | $1.78 Billion | +51.38% |
| 2022 | $1.18 Billion | +22.26% |
| 2021 | $962.45 Million | -8.65% |
| 2020 | $1.05 Billion | -28.79% |
| 2019 | $1.48 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Mirum Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.82 Billion USD |
| MoneyControl | $5.82 Billion USD |
| MarketWatch | $5.82 Billion USD |
| marketcap.company | $5.82 Billion USD |
| Reuters | $5.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more